22 April 2021: OIA response | Pembrolizumab and nivolumab Special Authority data

22 April 2021

Dear [name and contact details withheld] 

REQUEST FOR INFORMATION 

Thank you for your request dated 7 April 2021 under the Official Information Act 1982 (OIA) for information relating to pembrolizumab and nivolumab. You requested: 

…quarter 1 data by month on Special Authority’s – initial and renewal for the 2 immunotherapies funded for melanoma in New Zealand, pembrolizumab and nivolumab… 

Special Authority data for pembrolizumab and nivolumab

Following on from our previous response to you 17 February 2021 regarding your request for information, please refer below for an update of pembrolizumab and nivolumab Special Authority application numbers.

Pembrolizumab - SA1910

Month submitted

Initial Applications

Approvals - initial

Renewal Applications

Approval - Renewal

Total applications

Total approvals

2021-01-01

22

21

64

59

86

80

2021-02-01

16

14

41

38

57

52

2021-03-01

1

1

61

54

62

55

 Nivolumab - SA1911

Month submitted

Initial Applications

Approvals - initial

Renewal Applications

Approval - Renewal

Total applications

Total approvals

2021-01-01

0

0

4

3

4

3

2021-02-01

0

0

0

0

0

0

2021-03-01

0

0

0

0

0

0

Please note:

  • The data provided was correct as of 9 April 2021. It is likely incomplete, due to delays in applications being processed and entered into the system.
  • The data provided is a count of Special Authority approvals, not patients. They do not represent the number of patients being dispensed the relevant medicine in a given period.
  • If a patient has had more than one relevant Special Authority approval, they will be counted more than once in this data.

We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.

Yours sincerely

Rachel Read
Manager, Policy and Government Services